VITA 34 AG (DE:V3V)
XETRA:V3V
Want to see DE:V3V full AI Analyst Report?
V3V Stock Chart & Stats
€6.05
€0.00(0.00%)
At close: 4:00 PM EST
€6.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.80 - €7.65
Previous CloseN/A
Volume271.00
Average Volume (3M)1.65K
Market Cap
€69.03M
Enterprise Value€80.66M
Total Cash (Recent Filing)€11.88M
Total Debt (Recent Filing)€23.51M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding17,640,104
10 Day Avg. Volume2,079
30 Day Avg. Volume1,645
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)14.70
Price to Sales (P/S)1.19
P/FCF Ratio-420.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€85.00M
Bulls Say, Bears Say
Bulls Say
Niche Biobanking Business ModelVita 34’s end-to-end cord blood and perinatal tissue storage model creates recurring revenue from long-term storage contracts, high switching costs and specialized logistics/lab capabilities. These structural attributes support steady, subscription-like cash flows and durable customer relationships over time.
Long-term Revenue Expansion TrendThe multi-year growth trajectory through 2020–2024 demonstrates product-market fit and scalable distribution for Vita 34’s services. A historical expansion of revenues implies an established sales pipeline and market adoption that can underpin recovery after short-term dips and support medium-term margin improvement if volumes normalize.
Resilient Operating Cash GenerationPositive operating cash flow in 2025, alongside improvements like EBITDA turning positive and recovering gross profit, indicates the business can convert some sales into cash despite accounting losses. That operating cash resiliency reduces short-term financing dependence and gives management runway to focus on margin recovery and reinvestment.
Bears Say
Persistent Net LossesSustained losses since 2021 and negative EBIT in 2025 show the company has not yet converted top-line activity into consistent profitability. Persistent operating losses weaken returns metrics, constrain retained earnings accumulation, and mean management must continually manage costs or secure financing to sustain operations and strategic initiatives.
Weakened Equity And Rising LeverageA shrinking equity base alongside higher debt raises leverage and balance-sheet risk. The thinner capital cushion reduces flexibility to absorb shocks, increases refinancing sensitivity, and limits capacity for M&A or capital-intensive expansion without dilutive or costly funding, risking long-term strategic optionality.
Recent Revenue Contraction And FCF PressureA meaningful revenue decline in 2025 combined with a return to slightly negative free cash flow signals demand or execution headwinds and squeezes reinvestment capacity. That reversal undermines margin sustainability, raises the likelihood of further financing needs, and makes multi-year profit recovery less certain without clear corrective action.
V3V FAQ
What was VITA 34 AG’s price range in the past 12 months?
VITA 34 AG lowest stock price was €3.80 and its highest was €7.65 in the past 12 months.
What is VITA 34 AG’s market cap?
VITA 34 AG’s market cap is €69.03M.
When is VITA 34 AG’s upcoming earnings report date?
VITA 34 AG’s upcoming earnings report date is May 29, 2026 which is in 8 days.
How were VITA 34 AG’s earnings last quarter?
Currently, no data Available
Is VITA 34 AG overvalued?
According to Wall Street analysts VITA 34 AG’s price is currently Overvalued.
Does VITA 34 AG pay dividends?
VITA 34 AG pays a Annually dividend of €0.16 which represents an annual dividend yield of N/A. See more information on VITA 34 AG dividends here
What is VITA 34 AG’s EPS estimate?
VITA 34 AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 AG have?
VITA 34 AG has 17,640,104 shares outstanding.
What happened to VITA 34 AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VITA 34 AG?
Currently, no hedge funds are holding shares in DE:V3V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VITA 34 Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.44%
12-Months-Change
Fundamentals
Return on Equity
-52.70%
Trailing 12-Months
Asset Growth
10.16%
Trailing 12-Months
Company Description
VITA 34 AG
VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.